This study prospectively assessed the impact of treatment modality, virus load, and CD4 cell count of !50 cells/mm 3 Although highly active antiretroviral therapy (HAART) has noticeably and significantly reduced the morbidity and mortality associated with human immunodeficiency virus (HIV) type 1 infection [1, 2] , virologic treatment failure is frequent [3, 4] . The prognostic value of plasma HIV-1 RNA and CD4 cell count for clinical progression was originally measured in antiretroviral untreated or minimally treated patient populations [5, 6] .
Data from several cohorts indicate that CD4 cell counts may remain stable or continue to increase in patients on HAART, despite a rebound in plasma HIV-1 RNA levels [7] [8] [9] . Because the level of immunosuppression or immunocompetence deter-mines disease progression, CD4 cell count may be a better predictor for progression than plasma HIV-1 RNA levels for patients receiving HAART. On the other hand, a treatment benefit independent of both CD4 cell count and virus load was observed when patients receiving protease inhibitors (PIs) were compared with patients not receiving PI-containing therapies, although both virus load and CD4 cell count remained significant independent factors associated with disease progression [10] . Furthermore, treatment discontinuation in patients with virologic failure leads to rapid increases in virus load and declining CD4 cell count, which provides further evidence of a treatment benefit despite virologic failure [11, 12] . However, continuation of antiretroviral treatment in the presence of detectable levels of viral replication carry the risk of further viral evolution toward higher levels of resistance [13] and the development or worsening of existing drug toxicities. Thus, it is important to investigate the relationship between plasma HIV-1 RNA levels, CD4 cell counts, treatment modality, and disease progression in greater detail. From a clinical perspective, the management options for the increasing proportion of patients experiencing significant immunologic and virologic failure while receiving HAART are sparse; multidrug combinations of у6 drugs are frequently used without clinical endpoint data to support this practice [14, 15] .
A previous analysis of the EuroSIDA cohort indicated that disease progression in patients with low CD4 cell counts was related inversely to intensity of treatment. The incidence rates of clinical progression were 38-78 per 100 person-years of patient follow-up, according to the intensity of treatment, even though all patients had CD4 cell counts of р50 cells/mm 3 [16] . In another study, the incidence of AIDS-defining illnesses was significantly lower if patients were receiving HAART in each CD4 cell strata examined, and this was confirmed for 7 of 8 individual diagnoses [17] . In these 2 studies, the impact of plasma HIV-1 RNA and type of HAART treatment on disease progression could not be established. Historically, the majority of patients receiving HAART received PIs.
Our objective for the present analysis was to assess the impact of the treatment modality in combination with virus load and CD4 cell count on disease progression in patients with CD4 cell counts of р50 cells/mm 3 . In addition to CD4 cell count and virus load, we looked at hemoglobin levels [17] [18] [19] , body mass index (BMI), and the use of prophylaxis for opportunistic infections.
Subjects and Methods
Subjects and setting. The EuroSIDA study includes 18500 patients from 64 centers across Europe and Israel. Details of the study have been published elsewhere [17, 20] . In brief, patients у16 years old with CD4 cell count of р500 cells/mm 3 (restriction applies to cohorts 1-3) were recruited into the study. Information is collected from patient case notes onto a standardized data collection form at baseline and every 6 months thereafter. Data collected at each follow-up visit include the latest weight and hemoglobin measurements, all CD4 lymphocyte counts measured at the participating site since last the follow-up, and all virus load measurements (with the method used and the lower limit of detection). The date of starting and stopping each antiretroviral drug is recorded, as are drugs for prophylaxis against opportunistic infections. Dates of diagnosis of all AIDS-defining illnesses are also recorded as defined by the 1993 Centers for Disease Control and Prevention clinical definition of AIDS [21] . Members of the coordinating office visit all centers to ensure correct patient selection and accurate data collection. Follow-up for this analysis is to summer 2000.
Statistical analyses. Incidence rates of clinical progression (new AIDS or death) were calculated as number of events per 100 person-years of follow-up [22] within various strata of current calendar year, presence of a previous AIDS diagnosis, latest CD4 cell count (cells/mm 3 ), latest virus load (copies/mL) measurement, latest hemoglobin (g/L) measure, latest BMI (kg/m 2 ), number of drugs received 3 months previously, total drugs ever taken, and current use of Pneumocystis carinii pneumonia (PCP) and/or Mycobacterium avium complex (MAC) prophylaxis. The basic time units used were months. A given month for a given subject contributed to the person-years at risk if the most recent CD4 cell count and virus load were measured р6 months earlier, the most recent CD4 cell count was !50 cells/mm 3 , and the subject was under active followup in the EuroSIDA. Thus, person-months contributed by a given subject were not necessarily consecutive, depending on availability of virus load and CD4 cell counts and on whether CD4 cells were !50 cells/mm 3 . Eligible patients had у1 month of follow-up; the first such month was the baseline date for that patient.
When we considered the association with clinical progression of the number of drugs being taken, patient follow-up was allocated to the treatment regimen 3 months previously rather than that in the same month. This lag was used because of the tendency for all drugs to be stopped immediately before death and occasionally upon occurrence or diagnosis of an AIDS disease, and we wished to study the effect of the drug regimen on risk of death and not the converse. We calculated confidence intervals (CIs) for the incidence rates by using a normal approximation (if there were !20 events, Poisson distribution was used). Poisson regression models were used to assess predictors of disease progression.
In addition to grouping patients by number of drugs received 3 months earlier, we also grouped patients according to whether they were receiving a PI, a nonnucleoside reverse-transcriptase inhibitor (NNRTI), or nucleoside reverse-transcriptase inhibitors (NRTIs) only. We used generalized estimating equations with the Poisson models when we considered rates of new AIDS disease or death because we included multiple AIDS events for the same subject [23] . PCP prophylaxis was defined as use of cotrimoxazole, trimethoprimsulfamethoxazole, pentamidine, dapsone, or atovaquone. MAC prophylaxis was defined as the use of (any) ethambutol, rifabutin, or clarithromycin/azithromycin. All statistical analyses were performed by using SAS software (version 6.12; SAS Institute). Poisson regression was performed with PROC GENMOD software (SAS Institute).
Results

Patient population.
In total, 1106 patients satisfied the entry criteria for this study and yielded 808.0 person-years of followup. Table 1 shows the characteristics of the patients at the time they first met eligibility criteria (referred to as baseline). Of the subjects, 69% had a baseline date before January 1998, 83% were male, and 46% were infected through homosexual contact. The median CD4 cell count was 27 cells/mm 3 ; 53% of patients entered the study with CD4 cell counts of !30 cells/mm 3 . The median virus load at baseline was 4.8 log 10 copies/mL (63,000 copies/mL), and 56% of patients had 150,000 HIV copies/mL at study entry. Table 1 also shows the distributions for hemoglobin and BMI categories.
At baseline, 122 (11%) patients were not receiving any antiretroviral treatment (table 2), 68% were receiving у3 drugs (10% were receiving у5 drugs), 727 (74%) were receiving у1 PIs at baseline, 112 (11%) were receiving у1 NNRTIs, and 222 (23%) were receiving NRTIs only. Of those receiving у5 drugs, 58% were receiving ritonavir, compared with 43% receiving 4 drugs, and 18% receiving 3 drugs. Because the EuroSIDA database does not include drug doses, it is not possible to report whether ritonavir was being used only as a pharmacologic enhancer of drug levels of other PIs or at therapeutic levels. The majority of subjects (52%) had ever received 3-5 drugs; 29% had ever received у6 drugs ( 63 (6) prophylaxis use increased with increasing antiretroviral drug use: for patients receiving 0, 1, 2, 3, 4, or у5 drugs, PCP prophylaxis was used by 66%, 74%, 72%, 84%, 89%, and 92%, respectively, and MAC infection prophylaxis was used by 16%, 23%, 22%, 24%, 34%, and 39%, respectively. Clinical progression. For all follow-up comparisons, the median/mean (interquartile range) months since the most recent CD4 cell count was 1/1.7 months (0-3/0-6 months). For virus load the equivalent values were 1/1.5 months (0-2/0-6 months). In all, 443 clinical events occurred during the follow-up period. Of these, 190 (42.9%) were progressions to new AIDS events in patients with AIDS at baseline, 178 (40.2%) were deaths, and 75 (16.9%) were first AIDS-defining events. Thus, the overall incidence rate (AIDS-defining illnesses and death) was 54.8 (95% CI, 49.7-59.9) per 100 person-years of follow-up; the overall rate for death was 22.1 (95% CI, 18.9-25.3). The most common clinical events were esophageal candidiasis (20%), cytomegalovirus retinitis (12%), non-Hodgkin lymphoma (9%), PCP (8%), Kaposi sarcoma (7%), progressive multifocal leukoencephalopathy (6%), and disseminated MAC infection (5%).
Both the overall rate of clinical disease progression (a new Clinical progression according to latest virus load, CD4 cell count, or hemoglobin level in combination with number of drugs received. The combined effect of number of drugs received 3 months previously with latest virus load, CD4 cell count, and hemoglobin measurements on event rates is illustrated in figure  1 . This figure shows how the number of drugs affect clinical progression according to each of the other variables. The association between the number of drugs and clinical progression was generally consistent across the strata of other variables.
Predictors of disease progression. We next estimated the effect of all of the variables on disease progression to clinical ) and 0.83 (95% CI, 0.75-0.93; ), re-P ! .0001 P p .003 spectively. In contrast, a 1-log higher latest virus load was less significant and was associated with clinical progression only, with a rate ratio of 1.11 (95% CI, 1.01-1.23;
). Both P p .03 latest hemoglobin and BMI remained highly significantly associated with clinical progression ( and , re-P ! .002 P p .0009 spectively). Only hemoglobin remained a significant predictor for death ( ). We also considered weight, but, in this P ! .0001 analysis, BMI had a stronger association with risk of disease progression and death.
In contrast to the number of different drugs taken, the effect of the number of drugs in the regimen was striking. For clinical progression, receiving 4 versus у5 drugs was associated with an increased ratio of 1.82 (95% CI, 1.21-2.72; ), and P p .004 the rate ratios continued to increase with fewer drugs, with a ) and for progression to death (RR, 0.27; P 1 .0001 95% CI, 0.18-0.39; ), whereas those receiving MAC P ! .0001 prophylaxis were at a slightly raised risk of clinical progression ( ) . P p . 05 We also assessed the effect of class of drugs used (PI and NNRTI, PI but not NNRTI, NNRTI but not PI, and NRTI only) but this was not independently associated with risk of progression. Similarly, total time receiving antiviral therapy, total time receiving PI, total time receiving NNRTIs, total time receiving antiviral therapy with HIV-1 RNA level measured as 1500 copies (which relies on virus load actually being measured and thus is only a crude proxy for the true time with virus load actually 1500 copies/mL) were not significant for either endpoint. In a further analysis, we also included in the model a variable indicating whether or not one of the drugs was ritonavir, and this was not significantly independently associated with risk of disease progression. Results in table 4 were similar when we allowed CD4 cell count and virus load values to remain current for only 3 months instead of 6 months (n p ; 633.3 person-years; adjusted rate ratio for AIDS or death 1048 for virus load, 1.13;
) and for CD4 cell count (0.84; P p .02 ). We also fitted the number of drugs taken 3 months P p .0001 earlier as a continuous variable. The rate ratios per 1 less drug were 1.30 ( ) for new AIDS or death and 1.54 ( P ! .0001 P ! ) for death as end point. There was no significant inter-.0001 action between calendar time and these associations ( ). P 1 .1 Finally, we repeated the analysis by including the number of drugs in use 6 months rather than 3 months previously. For new events, the rate ratio for patients using 4, 3, 2, 1, and 0 
Discussion
In this analysis of patients with CD4 cell counts of !50 cells/ mm 3 , we found that disease progression and death are predicted by the latest CD4 cell count, hemoglobin measurement, BMI while receiving PCP prophylaxis, and number of drugs in the treatment regimen. AIDS status was a predictor for death only, and plasma HIV-1 RNA was a predictor for clinical progression only. Thus, our data suggest that it is helpful to continue antiviral therapy and prophylactic therapy, despite severe immunodeficiency and regardless of plasma HIV RNA levels, and that the benefit due to each therapy is independent of the other. The association between the number of antiviral drugs used could indicate that receiving у5 drugs may be more beneficial than the standard 3-drug combination therapy for this patient population. An alternative explanation is that there is a "reverse causality," such that the number of drugs a person is taking is a reflection of health status and that those patients able to manage more drugs have a lower risk of disease and death than those patients not able to take any or many drugs. This may also contribute to the strong effect attributable to PCP prophylaxis in our analysis.
In an attempt to reduce this reverse causality effect, we used the number of antiviral drugs a person was taking 3 months before the period of risk under consideration, rather than at the latest time. The greater this lag period, the less we would expect to see the influence of reverse causality; so, in a secondary analysis, this lag time was increased to 6 months. Although the magnitude of the association was reduced (as would be expected regardless of the direction of causality), a significant association was maintained, which suggests that a reverse causality effect is unlikely to fully explain the association.
The intensity of antiviral treatment appears to provide a treatment effect over and above that we can model with the surrogate markers of CD4 cells, virus load, use of prophylaxis, and the additional clinical markers of hemoglobin level and BMI. This effect may be due to the treatment itself and, as such, may be related to its potency or to the patient's adherence or alternatively be due to some effect of the treatment that we cannot yet measure. It is possible that in the identification of patients taking more than the standard (3-drug combination) antiviral therapy, we selected for patients who had a longer treatment phase and who lived longer for as yet unknown reasons. Our additional analyses (time on antiviral therapy), however, do not support this hypothesis.
Another finding of interest is that in patients with very low CD4 cell counts, the absolute number of CD4
ϩ cells does matter. Thus, patients with CD4 cell counts of !10 cells/mm 3 fare worse than patients with CD4 cell counts of у10 cells/mm 3 . Of the 2 surrogate markers, CD4 cell count was a stronger predictor for disease progression. Plasma HIV-1 RNA did not predict death in this patient population (
). This is in P p .17 agreement with previous studies that found CD4 cell count to be a better predictor for clinical progression in patients with very advanced HIV disease [19, 24] .
In previous studies, hemoglobin was found to be a prognostic marker [18, 19, [25] [26] [27] . Anemia may be a marker of ongoing, as yet undiagnosed opportunistic disease or a marker of general immune activation. Weight was not previously associated with progression, and it is of interest that BMI (a measure of weight standardized for height) was a prognostic marker in this study of patients with very advanced disease. It is likely that BMI is a better indicator of health status than weight alone. It will be of interest to confirm this finding in other studies.
Treatment management of patients with advanced HIV disease is becoming increasingly complex with issues of drug toxicity and requirement for comedications playing a significant role. In addition, these patients frequently have had extensive prior treatment experience and are experiencing virologic failure.
In our study, 84% of the patients had plasma HIV-1 RNA levels 110,000 copies/mL, and 29% had been exposed to у6 drugs. Our data raise the possibility that intensive antiretroviral treatment (у5 antiretroviral drugs) is of clinical benefit in this patient population. However, these results are based on followup in an observational cohort rather than by randomized assignment to various treatment modalities. Thus, care should be taken in the interpretation of these findings. It will be of interest to compare our results with those of randomized trials that are currently underway to address the issue of treatment intensity in persons with advanced HIV disease and treatment failure. Our study spans from January 1998 to the first quarter of 2000. Although the availability of treatment choices may have increased during the study period, this is unlikely to have influenced our findings as calendar time was not identified as a predictor in any of the models tested.
The finding of an independent treatment benefit is in agreement with findings in prior studies [7, 8, 10, 16, 17] , indicating a clinical and/or immunologic benefit to continuing treatment despite virologic failure and (possibly) viral drug resistance. This treatment effect could be due to a residual activity of the regimen in spite of decreased drug susceptibility, changes in virus characteristics due to accumulation of drug resistance-associated mutations (decreased fitness or replicative capacity and/or changes in pathogenicity), or to nonantiviral effects of the inhibitors. For example, HIV-1 PIs inhibit proteases of Candida albicans [28] and P. carinii [29] in in vitro models. In addition, they may be protective for CD4 cells against apoptosis [30] .
We found that use of PCP prophylaxis was associated with a markedly reduced risk of new AIDS and/or deathaA. Although this likely partly reflects the efficacy of prophylaxis, it could also be due to reverse causality, as discussed above. However, in contrast, use of MAC prophylaxis was associated with a somewhat raised rate of new AIDS/death, which was of borderline statistical significance (
). This could reflect some P p .05 residual confounding, with persons given such prophylaxis being at increased risk of new AIDS/death due to factors not captured and adjusted for in the multivariable model. Randomized trials have shown clinical benefit for MAC prophylaxis, and our results do not contradict the current recommendations for MAC prophylaxis [31] .
Patients with low CD4 cell counts are at a high risk of clinical progression. Unfortunately, many such persons have experienced previous treatment failures, potentially have drug-resistant virus, and may not have many therapeutic options available to them. Although it is difficult to exclude the possibility that some of the association is due to reverse causality-with healthier people able to tolerate more drugs-our results suggest that keeping these patients on antiviral treatment nevertheless is likely to be better than not giving any treatment at all. Although the risk-benefit evaluation should also include the risk for continued evolution of resistance [13, 32] and of possible long-term drug toxicities, our findings add further evidence that the risk-benefit ratio for clinical progression weighs in favor of treatment continuation rather than interruption in patients with virologic failure.
